Central hub coordinating efforts to cure multiple myeloma
Core 1: Administrative Core
This program coordinates international clinical trials and lab work to improve and personalize treatment for people with multiple myeloma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11179327 on NIH RePORTER |
What this research studies
This effort brings together teams at Dana‑Farber, Harvard, MIT, and partners in France to run trials and laboratory studies aimed at curing multiple myeloma. They are running an international trial that uses MRD (minimal residual disease) results after high‑dose melphalan and autologous stem cell transplant to guide further treatment choices. Collected patient samples will be analyzed for genomic and epigenomic changes, master transcription factor activity, long noncoding RNA dependencies, and mechanisms of genomic instability to identify new drug targets. The administrative core coordinates patient enrollment, sample handling, data management, and collaboration between clinical and laboratory projects.
Who could benefit from this research
Good fit: Ideal candidates are people with multiple myeloma who are eligible for high‑dose melphalan and autologous stem cell transplant and are willing to join international clinical trials and provide biological samples.
Not a fit: Patients without multiple myeloma, those not eligible for transplant, or those unable or unwilling to join participating centers are unlikely to benefit directly from this program.
Why it matters
Potential benefit: If successful, this work could help doctors tailor post‑transplant treatment based on MRD and discover targeted therapies that increase the chance of cure.
How similar studies have performed: Prior trials have shown that high‑dose melphalan with autologous stem cell transplant can achieve MRD‑negative status and improved survival, while using MRD to direct therapy and targeting lncRNAs or genomic instability are newer approaches with more limited prior evidence.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Munshi, Nikhil C. — Dana-Farber Cancer Inst
- Study coordinator: Munshi, Nikhil C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.